Cenobamate and Risperidone interaction

Cenobamate and Risperidone: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.

Moderate

Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.

What the FDA labels say

From the Cenobamate (Xcopri) label · effective 2025-08-25

Moderate

Concomitant use with other CNS depressants or alcohol may have additive effects.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when XCOPRI is used with other drugs with sedative properties because of potential additive effects.

Warnings and precautionsby drug classView label on DailyMed
Moderate

CNS Depressants and Alcohol Concomitant use of XCOPRI with other CNS depressants, including alcohol, may increase the risk of neurological adverse reactions, including sedation and somnolence [see Warnings and Precautions ( 5.5 )] .

Drug interactionsby drug classView label on DailyMed

From the Risperidone (RISPERDAL CONSTA) label · effective 2025-11-05

Moderate

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone.

Drug interactionsby drug classView label on DailyMed
Moderate

Carbamazepine and Other CYP 3A4 Enzyme Inducers Carbamazepine co-administration with oral RISPERDAL decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.

Drug interactionsby drug classView label on DailyMed
Moderate

Co-administration of other known CYP 3A4 enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of RISPERDAL CONSTA treatment.

Drug interactionsby drug classView label on DailyMed
Moderate

At the initiation of therapy with carbamazepine or other known hepatic enzyme inducers, patients should be closely monitored during the first 4–8 weeks, since the dose of RISPERDAL CONSTA may need to be adjusted.

Drug interactionsby drug classView label on DailyMed
Moderate

On discontinuation of carbamazepine or other CYP 3A4 hepatic enzyme inducers, the dosage of RISPERDAL CONSTA should be re-evaluated and, if necessary, decreased.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.